BMS, Roche deal

Bristol-Myers granted Roche rights to BMS-986089, a fusion protein designed to suppress myostatin (MSTN; GDF8). According to ClinicalTrials.gov, BMS-986089 is in Phase I/II testing to treat Duchenne m...